Simon Pacey
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (8)
Year:
2026
Year:
2026
Purpose: The purpose was to investigate combined PARP and androgen inhibition in primary prostate cancer and understand the biological mechanisms underlying clinical efficacy, especially in the absence of mutations in homologous recombination (HR) repair pathways. Patients and Methods: The primary objective was to measure PARP inhibition, and the secondary objectives were to assess safety and feasibility. Participants received olaparib for 2 weeks before prostatectomy and were randomly assigned or not assigned (1:1) to degarelix. We analyzed diagnostic biopsy and radical prostatectomy samples for PARylated protein expression using IHC. Exploratory analyses included tumor gene sequencing, mutation analysis, and RNA sequencing (RNA-seq) using both bulk and single-cell RNA-seq performed on pretreatment and posttreatment tissues. Results: PARylated protein expression was significantly reduced in both cohorts, with no drug-related delays in radical prostatectomy. The gene set enrichment analysis identified distinct treatment response signatures related to olaparib in both cohorts and showed downregulation of androgen response genes after olaparib + degarelix treatment. Transcript profiling revealed an upregulation of the p53 hallmark, which was more pronounced with the combination treatment. Canonical cell-cycle progression hallmarks, including E2F targets and the G2–M checkpoint, were suppressed across all cases, correlating with a HR-deficient transcriptional signature. Single-nuclear RNA-seq indicated a greater increase in inflammatory response pathway activity within tumor epithelia after combination treatment. Conclusions: Transcriptomic analysis identified common hallmark alterations reflecting the combined impact of PARP inhibitor and androgen blockade on cell-cycle progression. We observed a shared phenotypic response to combination therapy across prostate cancers without known HR repair gene alterations. This suggests alternative mechanisms rather than antiandrogen-induced HR deficiency.
Year:
2025
Year:
2025
Purpose: The purpose was to investigate combined PARP and androgen inhibition in primary prostate cancer and understand the biological mechanisms underlying clinical efficacy, especially in the absence of mutations in homologous recombination (HR) repair pathways. Patients and Methods: The primary objective was to measure PARP inhibition, and the secondary objectives were to assess safety and feasibility. Participants received olaparib for 2 weeks before prostatectomy and were randomly assigned or not assigned (1:1) to degarelix. We analyzed diagnostic biopsy and radical prostatectomy samples for PARylated protein expression using IHC. Exploratory analyses included tumor gene sequencing, mutation analysis, and RNA sequencing (RNA-seq) using both bulk and single-cell RNA-seq performed on pretreatment and posttreatment tissues. Results: PARylated protein expression was significantly reduced in both cohorts, with no drug-related delays in radical prostatectomy. The gene set enrichment analysis identified distinct treatment response signatures related to olaparib in both cohorts and showed downregulation of androgen response genes after olaparib + degarelix treatment. Transcript profiling revealed an upregulation of the p53 hallmark, which was more pronounced with the combination treatment. Canonical cell-cycle progression hallmarks, including E2F targets and the G 2 –M checkpoint, were suppressed across all cases, correlating with a HR-deficient transcriptional signature. Single-nuclear RNA-seq indicated a greater increase in inflammatory response pathway activity within tumor epithelia after combination treatment. Conclusions: Transcriptomic analysis identified common hallmark alterations reflecting the combined impact of PARP inhibitor and androgen blockade on cell-cycle progression. We observed a shared phenotypic response to combination therapy across prostate cancers without known HR repair gene alterations. This suggests alternative mechanisms rather than antiandrogen-induced HR deficiency.
Year:
2025
Gemcitabine plus cisplatin (GC) is effective in urothelial and other cancers. We investigated GC combined with escalating doses of temsirolimus (T), intravenous mTOR inhibitor. Adults with histologically confirmed solid tumours were enrolled. The primary endpoint was safety of GC with T, including dose limiting toxicity. Exploratory endpoints included pharmacokinetics and circulating tumour DNA (ctDNA) analyses. Fourteen participants (6 bladder cancer) were enrolled. Four dose levels were evaluated, adverse events were common and led to dose reductions, delays and omissions. Plasma concentrations of gemcitabine metabolites and cisplatin were unaffected by temsirolimus. ctDNA was detected in all samples taken from a sub set of patients. Levels of ctDNA changed earlier and correlated with imaging, while biologically relevant mutations e.g. PIK3CA were detected. Our results confirm the poor tolerability of three-drug combinations including GC and T but highlight the potential for ctDNA monitoring in Phase 1 cancer trials.
Year:
2025
The prospective, single-arm CALIBRATION trial (NCT03653052) assessed liquid biopsies for early response concordance compared with CT scan assessment in patients with advanced oesophageal cancer given durvalumab (PD-L1 inhibitor) after at least one prior systemic therapy. 19 participants received 1500mg of durvalumab every four weeks. ctDNA was analysed retrospectively with Guardant 360 ® CDx at baseline, weeks 4 and 7. Response at week 26 was assessed by RECIST v1.1. Tumour samples underwent 30X Whole Genome Sequencing. Concordance between ctDNA and CT results was pre-defined as either ≥50% increase in ctDNA mean variant allele frequency (VAF) with progressive disease, or ≥50% decrease in VAF correlating with radiological response or stable disease. At week four, 4/17 patients (23.5%) showed concordance; at week seven, this rose to 6/12 patients (50.0%). We reduced ctDNA VAF thresholds sequentially from ±50% to ±1% and identified that with any change in ctDNA at week 7, 75% of cases (9/12) showed concordance. 14/18 (77.7%) of patients progressed in the cohort at 6 months. All patients with ctDNA increases progressed. Our data supports assessing ctDNA at week seven rather than week four for immunotherapy response prediction. ctDNA VAF increases, especially, could aid decision-making in early-phase clinical trials to cease non-beneficial interventions.
Year:
2024
Year:
2023
Collaborators (12)
Vincent J. Gnanapragasam
Professor of Urology
University of Cambridge
Robert Jones
University of Glasgow
Javier García-Corbacho
Head of Early Drug Development Unit
-
Tamsin Robb
Research Associate
University of Cambridge
Mark Linch
Associate Professor of Oncology
-
Paul Loadman
Professor of Drug Metabolism and Pharmacokinetics
University of Bradford
Amit Roshan
Clinical Senior Lecturer
Queen Mary University of London
Daniel Brewer
Professor of Medical Bioinformatics and Genomics
University of East Anglia
Richard Baird
Clinical Research Professor in Breast Cancer Therapeutics
University of Cambridge
Tristan Barrett
-
Greg Shaw
Honorary Associate Professor
University College London
ANNE WARREN
Associate Lecturer
University of Cambridge
Make your next move.
Prepare your application
Review drafts before you send them.